OS Therapies Incorporated (OSTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $34.87M
Last updated: Nov 17, 2026 at 11:05 AM ET
OS Therapies Incorporated (OSTX) Stock Forecast
Analysts expect OS Therapies (OSTX) to earn -$0.70 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit.
- Fiscal year ending Dec 31, 2026
- -$0.70
- EPS consensus
- Fiscal year ending Dec 31, 2027
- $0.35
- EPS consensus, revenue $26.57M
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.70 | -$0.75 to -$0.64 | 3 | N/A | N/A | 4 |
| Dec 31, 2027 | $0.35 | -$0.22 to $1.41 | 3 | $26.57M | N/A | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.16 | -$0.20 to -$0.11 | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.78.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.70 | -$0.70 | -$0.70 | -$0.68 | -$0.78 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.35 | $0.35 | $0.35 | $0.32 | $0.36 | -2.8% |
Frequently Asked Questions About OSTX
What is the OSTX stock forecast?
Consensus analyst estimates put OS Therapies's EPS at -$0.70 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Buy.
How do analysts rate OSTX stock?
Of 4 analysts covering OS Therapies, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OSTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.70, with estimates from -$0.75 to -$0.64 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.35, with estimates from -$0.22 to $1.41 from 3 analysts.
What revenue do analysts expect from OS Therapies next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $26.57M.
How many analysts cover OSTX?
4 analysts rate OS Therapies stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OSTX pages: Overview, Earnings, Forecast, Financials, Competitors